Eli Lilly and Company (LLY)vsRapid Micro Biosystems Inc (RPID)
LLY
Eli Lilly and Company
$1,138.34
+0.15%
HEALTHCARE · Cap: $994.92B
RPID
Rapid Micro Biosystems Inc
$1.11
-3.48%
HEALTHCARE · Cap: $65.71M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 226378% more annual revenue ($79.67B vs $35.18M). LLY leads profitability with a 33.5% profit margin vs -145.6%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
RPID
Avoid30
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 30.0x book value
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : RPID
Revenue growth of 10.9% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : RPID
The primary concerns for RPID are EPS Growth, Market Cap, Debt/Equity.
Key Dynamics to Monitor
LLY profiles as a growth stock while RPID is a turnaround play — different risk/reward profiles.
RPID carries more volatility with a beta of 1.44 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 30/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Rapid Micro Biosystems Inc
HEALTHCARE · MEDICAL DEVICES · USA
Rapid Micro Biosystems Inc (RPID) is an innovative biotechnology firm at the forefront of revolutionizing microbiological quality control for the pharmaceutical and biotechnology industries. Utilizing advanced automated microbial detection technologies, RPID significantly improves the accuracy and efficiency of microbial testing, addressing the stringent regulatory requirements within these sectors. As the demand for rapid quality assurance solutions continues to grow, Rapid Micro is well-positioned to spearhead advancements in testing methodologies, ensuring product safety and integrity in highly regulated environments.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?